Gadofosveset
Gadofosveset: A Gadolinium-based MRI Contrast Agent[edit | edit source]
Gadofosveset, commercially known under the trade names Vasovist and Ablavar, is a gadolinium-based contrast agent primarily utilized for enhancing the clarity of Magnetic Resonance Imaging (MRI) scans. Distinct from conventional MRI contrast agents, Gadofosveset operates as a blood pool agent due to its preferential binding to human serum albumin, resulting in prolonged vascular enhancement.
Chemistry and Formulation[edit | edit source]
Gadofosveset, in its clinical form, is introduced as the trisodium salt. This salt formulation ensures stability and solubility when administered intravenously to patients[1].
Mechanism of Action[edit | edit source]
Gadofosveset's primary mechanism revolves around its capacity to bind with human serum albumin, which is the most abundant protein in human blood plasma. This interaction yields several significant outcomes:
- Prolonged Retention in Vascular System: Binding to albumin allows Gadofosveset to remain in the vascular system longer than other contrast agents, facilitating extended imaging sessions.
- Enhanced Image Clarity: Due to its longer residence time in the blood pool, it offers higher-resolution imaging, particularly of vascular structures, aiding in the diagnosis of vascular diseases[2].
Indications and Usage[edit | edit source]
Given its specific attributes, Gadofosveset is primarily indicated for:
- MRA (Magnetic Resonance Angiography): To visualize and assess vascular abnormalities, blockages, or malformations.
- Evaluation of Peripheral Vascular Diseases: To provide detailed images of peripheral arteries and assess the flow of blood[3].
Administration and Dosage[edit | edit source]
Gadofosveset is administered intravenously. The recommended dosage and injection rate vary depending on the patient's body weight and the specific imaging procedure being undertaken.
Side Effects and Precautions[edit | edit source]
While Gadofosveset is generally considered safe, some potential side effects include:
- Allergic reactions or hypersensitivity to the agent.
- Mild to moderate headaches or dizziness post-administration.
It is crucial to screen patients for any history of kidney disease before administering gadolinium-based agents due to the rare risk of nephrogenic systemic fibrosis[4].
Conclusion[edit | edit source]
Gadofosveset, with its unique binding affinity for human serum albumin, offers significant advantages in vascular imaging, particularly in MRA. Its development underscores the importance of tailoring contrast agents to specific diagnostic needs, enhancing the precision and clarity of medical imaging.
References[edit | edit source]
- ↑ Winter, P. M., & Caruthers, S. D. (2008). Molecular and nanoparticle contrast agents for MRI. Current Cardiovascular Imaging Reports, 1(3), 142-148.
- ↑ Sherry, A. D., & Caravan, P. (2009). Molecular MRI Contrast Agents. Topics in Magnetic Resonance Imaging, 20(3), 159-167.
- ↑ Caravan, P. (2009). Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chemical Society Reviews, 38(7), 2422-2431.
- ↑ Marckmann, P., & Skov, L. (2009). Nephrogenic systemic fibrosis: clinical picture and treatment. Radiologic Clinics, 47(5), 833-840.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
